Denali Therapeutics (DNLI) News Today $23.22 -0.07 (-0.30%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Stifel Nicolaus Upgrades Denali Therapeutics (NASDAQ:DNLI) to BuyDecember 18 at 1:38 AM | americanbankingnews.comY Intercept Hong Kong Ltd Sells 25,369 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Y Intercept Hong Kong Ltd lessened its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 64.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,823 shares of the company's stock after selling 25,369December 17 at 4:01 AM | marketbeat.comStifel Upgrades Denali Therapeutics (DNLI)December 16 at 1:25 PM | msn.comDenali Therapeutics (NASDAQ:DNLI) Shares Gap Up - Here's WhyDenali Therapeutics (NASDAQ:DNLI) Shares Gap Up - Still a Buy?December 16 at 11:43 AM | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Upgraded at Stifel NicolausStifel Nicolaus upgraded shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price target for the company in a research note on Monday.December 16 at 7:25 AM | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by BrokeragesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and eight have assDecember 16 at 2:39 AM | marketbeat.com65,033 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Bought by Nomura Asset Management Co. Ltd.Nomura Asset Management Co. Ltd. acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 65,033 shares of the company'sDecember 15 at 4:22 AM | marketbeat.comState Street Corp Lowers Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)State Street Corp decreased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 4.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,252,011 shares of the company's stock after sellingDecember 15 at 3:52 AM | marketbeat.comWellington Management Group LLP Grows Position in Denali Therapeutics Inc. (NASDAQ:DNLI)Wellington Management Group LLP raised its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 9.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,727,450 shares of the comDecember 8, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $9.72 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI)Point72 Asset Management L.P. lowered its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 68.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 333,530 shares ofDecember 8, 2024 | marketbeat.comWhy Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?December 7, 2024 | finance.yahoo.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Temasek Holdings Private LtdTemasek Holdings Private Ltd lowered its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,355,832 shaDecember 6, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Holocene Advisors LPHolocene Advisors LP grew its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 65.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 97,447 shares of the company'sDecember 6, 2024 | marketbeat.comDenali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s DiseaseDecember 6, 2024 | markets.businessinsider.comDenali Therapeutics announces first patient dosed in Phase 2a study of BIIB122December 6, 2024 | markets.businessinsider.comThe Manufacturers Life Insurance Company Has $6.03 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)The Manufacturers Life Insurance Company lifted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 20.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 206,819 shares of the company's stock after purchasing an additional 3December 6, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Reduces Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Charles Schwab Investment Management Inc. decreased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 4.1% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,015,810 shares of the company's stock after selling 43,494 sharDecember 5, 2024 | marketbeat.com26,900 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Erste Asset Management GmbHErste Asset Management GmbH acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 26,900 shares of the company's stock, valued at approximately $792,000December 4, 2024 | marketbeat.comCinctive Capital Management LP Raises Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Cinctive Capital Management LP boosted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 32.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,December 3, 2024 | marketbeat.comFmr LLC Purchases 7,596,508 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Fmr LLC increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 3,234.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,831,378 shares of the company's stock after acquiring an addiDecember 3, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 63.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,749,486 shaDecember 2, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Stake Lowered by Wasatch Advisors LPWasatch Advisors LP reduced its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 40.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 238,881 shares of the company'December 1, 2024 | marketbeat.comFred Alger Management LLC Boosts Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Fred Alger Management LLC raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 349.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 121,316 shares of the company's stock afteDecember 1, 2024 | marketbeat.comAlgert Global LLC Acquires 21,975 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Algert Global LLC lifted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 82.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,630 shares of the company's stock after purchasing an additNovember 29, 2024 | marketbeat.comIntech Investment Management LLC Acquires New Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Intech Investment Management LLC bought a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 29,543 shares of the company's stock,November 29, 2024 | marketbeat.comFisher Asset Management LLC Acquires 69,223 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Fisher Asset Management LLC grew its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 14.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 547,331 shares of the company's stock after purNovember 28, 2024 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Stake Lifted by Victory Capital Management Inc.Victory Capital Management Inc. boosted its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 163.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,900 shares of the company's stock after buyinNovember 27, 2024 | marketbeat.comDenali Therapeutics Advances Brain Disease TherapiesNovember 21, 2024 | markets.businessinsider.comDenali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven ratings firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to thNovember 21, 2024 | marketbeat.comDenali Has A Neurodegenerative Edge Despite Market SkepticismNovember 16, 2024 | seekingalpha.comLos Angeles Capital Management LLC Decreases Position in Denali Therapeutics Inc. (NASDAQ:DNLI)Los Angeles Capital Management LLC decreased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 47.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,940 shares oNovember 16, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Trading Down 8.3% - Here's What HappenedDenali Therapeutics (NASDAQ:DNLI) Stock Price Down 8.3% - Time to Sell?November 15, 2024 | marketbeat.comState of New Jersey Common Pension Fund D Decreases Position in Denali Therapeutics Inc. (NASDAQ:DNLI)State of New Jersey Common Pension Fund D decreased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 24.8% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 77,483 shares of the company's stock after selling 25,613 shares dNovember 15, 2024 | marketbeat.comOppenheimer Sticks to Their Buy Rating for Denali Therapeutics (DNLI)November 14, 2024 | markets.businessinsider.comInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 1,020 Shares of StockNovember 13, 2024 | insidertrades.comBaillie Gifford & Co. Sells 417,709 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Baillie Gifford & Co. trimmed its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 3.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,345,887 shares of the cNovember 12, 2024 | marketbeat.comPrincipal Financial Group Inc. Increases Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Principal Financial Group Inc. increased its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 13.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,238,476 shares of the company's stock after purchasing an additional 149,939 shares during thNovember 12, 2024 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Reaches New 12-Month High - Still a Buy?Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month High - Time to Buy?November 11, 2024 | marketbeat.comDenali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comWhat is B. Riley's Estimate for DNLI Q1 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued to investors on Friday, November 8th. B. Riley analyst M. Mamtani anticipates that the company wiNovember 11, 2024 | marketbeat.comFY2024 Earnings Estimate for DNLI Issued By HC WainwrightDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities researchers at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Denali Therapeutics in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that theNovember 11, 2024 | marketbeat.comWedbush Cuts Earnings Estimates for Denali TherapeuticsDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at Wedbush cut their FY2024 earnings estimates for shares of Denali Therapeutics in a note issued to investors on Thursday, November 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($2.72November 11, 2024 | marketbeat.comDenali Therapeutics: Strategic Advancements and Financial Strength Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Estimate for DNLI EarningsDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at HC Wainwright lowered their FY2027 EPS estimates for shares of Denali Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $1November 8, 2024 | marketbeat.comDenali Therapeutics (DNLI) Receives a Hold from Stifel NicolausNovember 7, 2024 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)November 7, 2024 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPSDenali Therapeutics (NASDAQ:DNLI - Get Free Report) released its earnings results on Wednesday. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the firm earned ($0.72) earnings per share.November 7, 2024 | marketbeat.comDenali Therapeutics' (DNLI) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $90.00 price target on shares of Denali Therapeutics in a report on Thursday.November 7, 2024 | marketbeat.comPromising Developments and Strategic Advancements Propel Denali Therapeutics’ Buy RatingNovember 7, 2024 | markets.businessinsider.comDenali Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 6, 2024 | globenewswire.com Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address A conspiracy Trump won’t unseal (Ad)New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous. This is the untold, true story of God’s Investment. DNLI Media Mentions By Week DNLI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNLI News Sentiment▼1.340.71▲Average Medical News Sentiment DNLI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNLI Articles This Week▼94▲DNLI Articles Average Week Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Neurocrine Biosciences News Today Bio-Techne News Today Vaxcyte News Today Qiagen News Today Exelixis News Today Repligen News Today Revolution Medicines News Today Halozyme Therapeutics News Today Krystal Biotech News Today Arcellx News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNLI) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
